Tsujihashi H, Ishihara H, Nakanishi A, Matsuda H, Uejima S, Akiyama T, Kurita T
Nihon Hinyokika Gakkai Zasshi. 1989 Feb;80(2):204-9. doi: 10.5980/jpnjurol1989.80.204.
The effect of lymphokine-activated killer (LAK) cells on bladder tumor was examined in vivo and in vitro. In the in vitro experiment, 51Cr-cytotoxic assay was performed for which PBL were used as effector cells. A LAK activity of 26.6% was observed in PBL cultured with IL2 for 4 days, whereas OK-432-induced LAK activity was 22%. Furthermore, in the in vivo experiment, the anti-tumor effect of LAK cells was evaluated in human bladder tumor transplanted into nude mouse. IL2, OK432-induced LAK cells were injected intratumorally. In the LAK-treated group, inhibition of tumor growth was seen. Histologically, it was demonstrated that infiltrating lymphocytes were scattered around tumor cells. The augmentation of NK activity in spleen cells was observed in the LAK-treated group. Although further studies are required to establish its full significance, these findings suggest that immunotherapy against bladder tumors is hopeful.
研究了淋巴因子激活的杀伤（LAK）细胞对膀胱肿瘤的体内和体外作用。在体外实验中，以外周血淋巴细胞（PBL）作为效应细胞进行了51Cr细胞毒性测定。在用白细胞介素2（IL2）培养4天的PBL中观察到26.6%的LAK活性，而OK-432诱导的LAK活性为22%。此外，在体内实验中，在移植到裸鼠体内的人膀胱肿瘤中评估了LAK细胞的抗肿瘤作用。将IL2、OK432诱导的LAK细胞瘤内注射。在LAK治疗组中，观察到肿瘤生长受到抑制。组织学检查表明，浸润淋巴细胞散在于肿瘤细胞周围。在LAK治疗组中观察到脾细胞中NK活性增强。尽管需要进一步研究以确定其全部意义，但这些发现表明，针对膀胱肿瘤的免疫治疗是有希望的。
